Specifically, SGLT2is suppress the activation of the nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3 (NLRP3) inflammasome—a key driver of inflammation—and inhibit fibrosis progression in MASLD and MASH [24]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.